Salt and crystalline form of furopyrimidine compound and pharmaceutical use thereof
US12227513B2 · kind B2 · utility
0Cited by
1References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 25, 2019 |
| Grant date | Feb 18, 2025 |
| Priority date | — |
| Expiry date | Mar 24, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Salts and crystalline forms of (R)-4-((2-(1-(2-fluoro-6-(trifluoromethyl)benzyl)-2,4-dioxo-1′-((5-(trifluoromethyl)furan-2-yl)methyl)-1H-spiro[furo[3,4-d]pyrimidine-5,4′-piperidine]-3(2H,4H,7H)-yl)-1-phenylethyl)amino)butanoic acid (formula (1)) show excellent physicochemical properties including, for example, hygroscopicity, related substances, chemical stability. The salts and crystalline forms are useful and suitable for pharmaceutical uses such as the preparation of a pharmaceutical composition containing the same as an active ingredient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.